SYMPOSIUM OVERVIEW

The field of breast cancer therapy is rapidly evolving, and new active treatment options are emerging with increasing frequency. The New Horizons in Antimetabolite Therapy for Breast Cancer satellite to the 2006 San Antonio Breast Cancer Symposium will update oncologists on the latest developments in the use of antimetabolites in the treatment of early or advanced/metastatic breast cancer and how to integrate these findings into their everyday practices. This symposium will discuss the optimization of treatment regimens for metastatic breast cancer as well as the efficacy of antimetabolite/taxane combinations. Data regarding the use of nucleoside analogues in neoadjuvant therapy or in combination with targeted agents will be presented. Finally, future directions, including ongoing trials investigating the use of antimetabolites in combination with new cytotoxics, novel targeted agents, and in adjuvant therapy regimens for patients with early-stage breast cancer will be reviewed. A case-based discussion will provide attendees with the opportunity to interact with faculty and to gain insight into the application of research results to patient treatment decisions in their clinical practices.

TARGET AUDIENCE

This satellite symposium is designed to be of high clinical utility to medical oncologists with an interest in the treatment of breast cancer. No specific skills or knowledge other than a basic training in oncology are required for successful participation in this activity. Fellows, nurses, and pharmacists are also invited to attend.

CME ACCREDITATION AND DESIGNATION

Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

LEARNING OBJECTIVES

At the conclusion of this symposium, you should be able to:

• Compare the efficacy and safety of sequential versus combination chemotherapy for patients with hormoneindependent breast cancer
• Review results from clinical trials investigating the use of nucleoside analogues in combination with taxanes for the treatment of metastatic breast cancer
• Evaluate the clinical utility of nucleoside analogues as primary treatment for patients with early-stage breast cancer
• Discuss the prospects for combining antimetabolites with novel targeted agents
• List ongoing clinical trials exploring the utility of incorporating antimetabolites into adjuvant regimens for the treatment of early-stage breast cancer

DISCLOSURE OF COMMERCIAL INTEREST

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities.

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These speakers for the New Horizons in Antimetabolite Therapy for Breast Cancer symposium have disclosed the following relationship with the companies listed:

ACKNOWLEDGEMENT

This activity is supported by an educational grant from:

Lilly Oncology